We are live on
!
Find out more
VanEck Associates Portfolio holdings
AUM
$133B
1-Year Est. Return
72.99%
This Fund
S&P 500
This Quarter
Est. Return
+0.9%
1 Year Est. Return
+72.99%
3 Year Est. Return
+157.94%
5 Year Est. Return
+206.35%
10 Year Est. Return
+770.56%
AUM
$19.9B
AUM Growth
-$564M
(-2.7%)
Cap. Flow
+$537M
Cap. Flow
% of AUM
2.69%
Top 10 Holdings %
Top 10 Hldgs %
34.1%
Holding
863
New
72
Increased
399
Reduced
357
Closed
29
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kinross Gold
KGC
|
+$280M |
| 2 |
Compañía de Minas Buenaventura
BVN
|
+$273M |
| 3 |
SLB Ltd
SLB
|
+$80.3M |
| 4 |
Wheaton Precious Metals
WPM
|
+$78.2M |
| 5 |
Royal Gold
RGLD
|
+$64M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Newmont
NEM
|
+$62.5M |
| 2 |
Sibanye-Stillwater
SBSW
|
+$58.5M |
| 3 |
B
Barrick Mining
B
|
+$53.5M |
| 4 |
TSMC
TSM
|
+$49.5M |
| 5 |
Franco-Nevada
FNV
|
+$32.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Materials | 57.3% |
| 2 | Energy | 10.02% |
| 3 | Healthcare | 5.89% |
| 4 | Technology | 5.52% |
| 5 | Financials | 3.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
CVS Health
CVS
$135B
| $9.91M | 0.05% |
151,276
-266,782
| -64% | -$19.9M |
|
227
Jazz Pharmaceuticals
JAZZ
$16.1B
| $9.88M | 0.05% |
79,671
+6,502
| +9% | +$965K |
|
228
Nuveen AMT-Free Municipal Credit Income Fund
NVG
$2.67B
| $9.77M | 0.05% |
698,965
+60,788
| +10% | +$834K |
|
229
Nuveen AMT-Free Quality Municipal Income Fund
NEA
$3.36B
| $9.54M | 0.05% |
775,112
+35,050
| +5% | +$430K |
|
230
Nuveen Quality Municipal Income Fund
NAD
$2.73B
| $9.52M | 0.05% |
759,067
+28,292
| +4% | +$354K |
|
231
Teva Pharmaceuticals
TEVA
$40.4B
| $9.27M | 0.05% |
600,915
+44,349
| +8% | +$909K |
|
232
AGCO
AGCO
$8.41B
| $9.08M | 0.05% |
163,097
+1,031
| +0.6% | +$58.2K |
|
|
WBA
233
DELISTED
Walgreens Boots Alliance
WBA
| $9.02M | 0.05% |
132,020
-20,039
| -13% | -$1.55M |
|
234
United Therapeutics
UTHR
$26.1B
| $8.92M | 0.04% |
81,924
-735
| -0.9% | -$85.2K |
|
235
Prologis
PLD
$136B
| $8.8M | 0.04% |
149,828
+12,050
| +9% | +$781K |
|
236
ON Semiconductor
ON
$30.7B
| $8.74M | 0.04% |
529,706
-205,419
| -28% | -$3.55M |
|
237
Neurocrine Biosciences
NBIX
$18.2B
| $8.62M | 0.04% |
120,729
-865
| -0.7% | -$82.9K |
|
|
IFFT
238
DELISTED
International Flavors & Fragrances Inc. 6.00% Tangible Equity Units
IFFT
| $8.61M | 0.04% |
169,864
-12,038
| -7% | -$660K |
|
239
Bausch Health
BHC
$1.75B
| $8.59M | 0.04% |
464,915
-50,565
| -10% | -$1.2M |
|
|
GPL
240
DELISTED
Great Panther Mining Limited
GPL
| $8.54M | 0.04% |
1,202,408
-309,057
| -20% | -$2.04M |
|
241
Alnylam Pharmaceuticals
ALNY
$38.3B
| $8.46M | 0.04% |
116,045
+4,622
| +4% | +$356K |
|
242
Starwood Property Trust
STWD
$6.12B
| $8.16M | 0.04% |
413,862
+54,193
| +15% | +$1.17M |
|
243
Hercules Capital
HTGC
$2.99B
| $8.15M | 0.04% |
737,954
+12,368
| +2% | +$151K |
|
|
EMAG
244
DELISTED
VanEck Vectors Emerging Markets Aggregate Bond ETF
EMAG
| $8.02M | 0.04% |
400,000
| – | – |
|
245
Golub Capital BDC
GBDC
$3.33B
| $7.98M | 0.04% |
494,290
-12,215
| -2% | -$217K |
|
246
Rithm Capital
RITM
$5.58B
| $7.89M | 0.04% |
555,599
+92,515
| +20% | +$1.56M |
|
247
Qorvo
QRVO
$7.9B
| $7.69M | 0.04% |
126,608
-57,361
| -31% | -$3.86M |
|
|
CTLT
248
DELISTED
CATALENT, INC.
CTLT
| $7.45M | 0.04% |
238,850
+39,275
| +20% | +$1.52M |
|
249
Perrigo
PRGO
$1.44B
| $7.44M | 0.04% |
192,007
-8,737
| -4% | -$555K |
|
250
VanEck Green Bond ETF
GRNB
$184M
| $7.42M | 0.04% |
290,000
-10,000
| -3% | -$254K |
|
Similar funds
DAM
VanEck Associates's Q4 2018 Portfolio in Review
As of Q4 2018, VanEck Associates held 863 positions worth $19.9B, down 2.7% from $20.5B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
VanEck Associates's Q4 2018 filing shows 72 new, 399 increased, 357 reduced and 29 closed positions. Its largest new stake was Equifax: 224,466 shares worth $20.9M. The largest sale was Newmont, an estimated $62.5M.
By sector, the portfolio is most concentrated in Materials at 57% of assets, up from 48% a quarter earlier, followed by Energy and Healthcare.
- VanEck Associates's largest Q4 2018 buy was Equifax: 224,466 shares worth $20.9M.
- VanEck Associates added most to Kinross Gold in Q4 2018, an estimated $280M increase.
- VanEck Associates's biggest Q4 2018 reduction was Newmont, cutting an estimated $62.5M.
- VanEck Associates fully exited Energen in Q4 2018, selling an estimated $23.2M.
- VanEck Associates's ten largest holdings make up 34% of its $19.9B portfolio in Q4 2018.
- VanEck Associates opened 72 new positions and closed 29 in Q4 2018.
- VanEck Associates's portfolio value fell 2.7% quarter-over-quarter to $19.9B.
Based on VanEck Associates's 13F filing for Q4 2018, filed 12 Feb 2019.